APA (7th ed.) Citation

Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, & Josie Solomon. (2023). The reimbursement process in three national healthcare systems: Variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, and Josie Solomon. The Reimbursement Process in Three National Healthcare Systems: Variation in Time to Reimbursement of Pembrolizumab for Metastatic Non-small Cell Lung Cancer. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Sarah Sharman Moser, et al. The Reimbursement Process in Three National Healthcare Systems: Variation in Time to Reimbursement of Pembrolizumab for Metastatic Non-small Cell Lung Cancer. Taylor & Francis Group, 2023.